Enterome Highlights High Complete Response Rate in Clinical
- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients ...
Read more- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients ...
Read morePARIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.